This editorial describes the science behind a study of axatilimab to treat chronic graft-versus-host disease.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Science behind the Study: CSF1R Blockade for Refractory Chronic Graft-versus-Host Disease
